Análisis de 1.000 casos de estudios metabólicos en Chile con PET 18Flúor-deoxiglucosa (FDG)
Background: Clinical oncology is the main application of 18F-deoxyglucose (FDG) positron emission tomography (PET). Aim: To evaluate the first 1,000 patients studied with FDG PET in Chile. Material and methods: Retrospective analysis of 1,000 patients (aged between 1 and 94 years, 550 females) studi...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Lenguaje: | Spanish / Castilian |
| Publicado: |
Sociedad Médica de Santiago
2007
|
| Materias: | |
| Acceso en línea: | http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872007000300014 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Background: Clinical oncology is the main application of 18F-deoxyglucose (FDG) positron emission tomography (PET). Aim: To evaluate the first 1,000 patients studied with FDG PET in Chile. Material and methods: Retrospective analysis of 1,000 patients (aged between 1 and 94 years, 550 females) studied with FDG PET, since 2003. All studies were performed in a high resolution Siemens Ecat-Exact HR (+). All reports were based on the visual analysis of three plane and three-dimensional images. Results: Ninety seven percent of exams were done for oncological indications, mainly lung lesions, lymphoma, colorectal and gastroesophageal, cancer and breast tumors. Only 1% of patients had brain tumors. Non tumor neurological indications corresponded to 1.7%. Cardiac studies were only 0.3% and inflammatory process corresponded to 1%. The 5.6% corresponded to pediatric population. Six percent of patients were aged less than 18 years and in 50% of them, the indication was oncological, mainly lymphomas, brain tumors, endocrine cancers and sarcomas. The remaining 50% had a neurological indications, mainly for refractory epilepsy. Conclusions: PET FDG imaging was effective in the management of diverse diseases of children and adults |
|---|